Table 3.
Feature | HR | CI (2.5–97.5%) | p-Value | |
---|---|---|---|---|
Serum zinc level | A | 1.956 | 1.21–3.17 | <0.01 |
B | 1.344 | 0.82–2.21 | 0.245 | |
C | 1.0 | |||
Sex | F | 1.0 | - | - |
M | 0.668 | 0.4–1.12 | 0.127 | |
Clinical stage | I | 1.0 | - | - |
II | 2.33 | 0.93–5.83 | 0.07 | |
III | 2.23 | 0.98–5.07 | 0.056 | |
IV | 7.304 | 3.28–16.26 | <0.01 | |
Chemotherapy | Yes | 0.802 | 0.43–1.51 | 0.494 |
No | 1.0 | - | - | |
Radiotherapy | Yes | 1.197 | 0.73–1.96 | 0.473 |
No | 1.0 | - | - | |
Pack-years | 1.011 | 1–1.02 | 0.069 | |
Age | ≤60 | 1.0 | - | - |
>60 | 1.37 | 0.92–2.04 | 0.122 | |
GPX1 | TC/TT | 0.987 | 0.67–1.44 | 0.945 |
CC | 1.0 | |||
SOD2 | TC/TT | 1.042 | 0.68–1.59 | 0.847 |
CC | 1.0 | |||
CAT | TC/TT | 1.09 | 0.74–1.6 | 0.661 |
CC | 1.0 |